Cargando…

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells

Although CAR T-cell therapy has demonstrated tremendous clinical efficacy especially in hematological malignancies, severe treatment-associated toxicities still compromise the widespread application of this innovative technology. Therefore, developing novel approaches to abrogate CAR T-cell-mediated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koristka, Stefanie, Ziller-Walter, Pauline, Bergmann, Ralf, Arndt, Claudia, Feldmann, Anja, Kegler, Alexandra, Cartellieri, Marc, Ehninger, Armin, Ehninger, Gerhard, Bornhäuser, Martin, Bachmann, Michael P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768917/ https://www.ncbi.nlm.nih.gov/pubmed/31414180 http://dx.doi.org/10.1007/s00262-019-02376-y

Ejemplares similares

Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
por: Mitwasi, Nicola, et al.
Publicado: (2017)

Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
por: Bachmann, Dominik, et al.
Publicado: (2017)

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
por: Feldmann, Anja, et al.
Publicado: (2017)

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
por: Cartellieri, M, et al.
Publicado: (2016)

Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8
por: Michalk, Irene, et al.
Publicado: (2014)

T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression
por: Kegler, Alexandra, et al.
Publicado: (2019)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
por: Loff, Simon, et al.
Publicado: (2020)

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML
por: Meyer, Jan-Erik, et al.
Publicado: (2021)

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts
por: Aliperta, R, et al.
Publicado: (2015)

Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy
por: Aliperta, Roberta, et al.
Publicado: (2017)

A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR
por: Arndt, Claudia, et al.
Publicado: (2019)

UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells
por: Arndt, Claudia, et al.
Publicado: (2020)

Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
por: Arndt, Claudia, et al.
Publicado: (2020)

An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells
por: Jureczek, Justyna, et al.
Publicado: (2019)

Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab(®)
por: Jureczek, Justyna, et al.
Publicado: (2020)

Cytotoxic response of human regulatory T cells upon T-cell receptor-mediated activation: a matter of purity
por: Koristka, S, et al.
Publicado: (2014)

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity
por: Cartellieri, Marc, et al.
Publicado: (2013)

Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR)
por: Mitwasi, Nicola, et al.
Publicado: (2022)

A Novel Ex Vivo Isolation and Expansion Procedure for Chimeric Antigen Receptor Engrafted Human T Cells
por: Cartellieri, Marc, et al.
Publicado: (2014)

Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy
por: Kittel-Boselli, Enrico, et al.
Publicado: (2021)

From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo
por: Albert, Susann, et al.
Publicado: (2018)

Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers
por: Loureiro, Liliana R., et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy in acute myeloid leukemia
por: Koedam, Jan, et al.
Publicado: (2022)

Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells
por: Loureiro, L. R., et al.
Publicado: (2018)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T Cells
por: Lindner, Diana, et al.
Publicado: (2022)

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
por: Ehninger, A, et al.
Publicado: (2014)

Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells
por: Saleh, Haidy A., et al.
Publicado: (2023)

Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy
por: Feldmann, Anja, et al.
Publicado: (2020)

T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
por: Mehta, Palak H., et al.
Publicado: (2021)

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
por: Li, Tongjuan, et al.
Publicado: (2019)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling
por: Mc Laughlin, Anna M., et al.
Publicado: (2023)

The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in
por: Ehninger, Armin, et al.
Publicado: (2011)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
por: Arjomandnejad, Motahareh, et al.
Publicado: (2022)

A cluster-randomised, controlled proof-of-concept study to explore the feasibility and effect of a patient-directed intervention on quality of life in patients with advanced soft tissue sarcoma
por: Schuler, Markus, et al.
Publicado: (2017)

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
por: Dickinson, Michael J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cmc04juk8ufo5vap52qi1p0gfq